Key Takeaways
- Cyber resilience in pharma must be measured by the continuity of medicine supply, not just by how fast IT systems are restored.
- Technical defences have improved, but many programmes lack clear business accountability and do not answer leaders’ questions about patient impact.
- A medicine‑value‑chain perspective links cybersecurity, business continuity and operational decisions, revealing cascading risks that affect batch release, inventory and regulatory standing.
- Modern operating models—automated manufacturing, AI‑driven research, cloud platforms and globally distributed suppliers—create new dependencies that amplify cyber exposure.
- Recent high‑profile incidents (Stryker 2026, Inotiv 2025) demonstrate how third‑party disruptions can ripple through the ecosystem and threaten patient access.
- Business‑led resilience assigns explicit ownership and decision‑rights to senior leaders, ensuring that cyber recovery aligns with the ability to release and deliver medicines.
- A four‑step value‑chain approach (map critical functions, assess cyber risk, identify choke points, design targeted mitigations) shifts focus from individual assets to end‑to‑end patient impact.
- Effective mitigation may include stricter third‑party requirements, inventory buffers, alternative sourcing, operational‑technology segmentation and predefined work‑arounds.
- Pharma leaders should treat the medicine value chain as the unit of cyber resilience, using disruption scenarios to guide investment, recovery priorities and governance, supported by cross‑sector platforms such as the World Economic Forum’s Centre for Cybersecurity.
Shifting Focus from Systems to Medicine Availability
Cyber resilience in the pharmaceutical and life‑sciences sector has evolved beyond the traditional goal of protecting networks and applications. The paramount objective now is to guarantee that medicines remain available to patients, even when cyber incidents occur. This shift recognises that a restored system does not automatically translate into uninterrupted patient care; production halts, delayed batch releases or blocked distribution can still jeopardise health outcomes. Consequently, resilience metrics must encompass the ability to maintain a secure and continuous medicine supply throughout the entire recovery process.
Current Technical Defences versus the Accountability Gap
Pharma companies have invested heavily in firewalls, endpoint protection, identity management and other technical safeguards, resulting in stronger barriers against many cyber threats. Yet, despite these upgrades, numerous cyber‑resilience programmes struggle to secure genuine business ownership. Technology‑centric initiatives often fail to articulate how a disruption would affect medicine availability, leaving senior leaders without clear answers to critical questions such as “How much downtime can we tolerate before patient care suffers?” or “Which work‑arounds remain safe and compliant?” This disconnect hampers effective governance and limits the strategic value of cyber investments.
Medicine Value Chain‑Based Approach to Cyber Resilience
Linking cybersecurity directly to the medicine value chain offers a framework that bridges the technical‑business divide. By mapping the end‑to‑end flow—from research and development, through manufacturing and quality control, to logistics and patient delivery—organisations can see where cyber risks intersect with critical operational nodes. This approach aligns cyber resilience with business continuity planning and operational decision‑making, ensuring that investments protect not just data but the ability to discover, develop, manufacture, release and deliver medicines safely and reliably.
Why Measuring Restoration Time Is Insufficient
Traditional resilience metrics focus on Mean Time to Restore (MTR) or similar system‑centric indicators. In pharma, however, ransomware that encrypts manufacturing execution systems, compromises supply‑chain platforms, or disrupts operational‑technology (OT) can halt production or delay batch release even after IT services are back online. Such cascading effects may deplete inventories, trigger regulatory scrutiny, and ultimately limit patient access. Therefore, resilience must be evaluated by the extent to which medicine supply continuity is preserved, not merely by how quickly computers reboot.
Evolving Operating Models Expand Cyber Exposure
The industry’s rapid adoption of automated manufacturing lines, AI‑enabled drug discovery, cloud‑based research environments and globally dispersed supplier networks has unlocked new value but also introduced fresh dependencies. Each digital touchpoint—whether a laboratory information management system, a third‑party contract research organisation, or a logistics portal—creates a potential entry point for cyber adversaries. As these models become more interconnected, the attack surface widens, making it essential to view resilience through a holistic, value‑chain lens rather than isolated assets.
Recent Cyber Incidents Illustrate Systemic Risks
Real‑world events underscore how external cyber incidents can reverberate through the pharma ecosystem. In March 2026, a ransomware attack on medical‑device maker Stryker disrupted its manufacturing, ordering and distribution channels, prompting NHS England to ask partners to prioritize clinically important supplies and reassess dependence on Stryker products. Earlier, in August 2025, contract research organisation Inotiv disclosed that threat actors had encrypted systems and blocked access to key applications and data, forcing the company to invoke its business‑continuity plan and shift some operations offline. Both cases show that disruptions at suppliers, CROs or logistics partners can directly affect medicine availability, even when the victimised firm’s own systems remain intact.
Business‑Led Resilience: Ownership, Decision Rights and Distinction from Cyber Recovery
For cyber resilience to become a true business enabler, programmes must shift from asset‑led to business‑led models. This means assigning explicit ownership and decision‑making authority to senior business leaders for the most critical value‑chain segments. Such leaders can answer the core questions of impact, tolerance and compliance, whereas a purely technical team may only know how to restore a server. Importantly, cyber recovery (bringing systems back online) is not synonymous with business resilience (ensuring that medicines can still be released and delivered). A restored application may still leave a plant unable to release a product if quality evidence is missing, while a supplier outage may be manageable if inventory buffers, alternative sources or manual procedures exist.
Reframing the Conversation: Four‑Step Value‑Chain Resilience Approach
A value‑chain resilience discussion begins by identifying the essential outcomes—discovering, developing, manufacturing, releasing and delivering medicines—and then mapping the entire chain that supports them, including internal functions, external partners, digital assets, data flows, OT and third‑party links. The next step assesses cyber risk and the potential impact of disruption on each critical node. From this analysis, organisations can define targeted mitigations: stricter supplier qualifications, recovery exercises, inventory buffers, OT segmentation, predefined manual fallbacks and clarified decision rights. Engaging manufacturing, quality, supply‑chain, regulatory, procurement, business‑continuity and cyber leaders in a single forum ensures that recovery priorities reflect patient‑impact timelines rather than abstract system criticality.
Call to Action, Leadership Shift and the Role of the Forum
The World Economic Forum’s Global Cybersecurity Outlook 2026 reveals that only one‑third of organisations comprehensively map their supply‑chain ecosystems and fewer than one‑third simulate cyber incidents or run recovery exercises. For pharma, the imperative is clear: assign explicit business ownership to essential value chains, use realistic disruption scenarios to guide investment and recovery decisions, and treat the medicine value chain as the unit of resilience. Cyber leaders must evolve from merely explaining technical exposure to enabling business decisions about patient‑care continuity, risk tolerance and operations recovery. Platforms such as the Centre for Cybersecurity provide a trusted space for cross‑sector collaboration, insight sharing and collective problem‑solving, helping leaders build the understanding and trust needed to safeguard medicine supply in an increasingly interconnected digital world.